MMTX — MindMaze Therapeutics Holding SA Share News
0.000.00%
Last trade - 00:00- CH₣34.12m
- CH₣24.65m
- CH₣0.64m
Swiss stocks - Factors to watch on June 10
Brief: SIX Exchange Regulation Opens Investigation Against Relief Therapeutics For Possible Violation Of Ad-Hoc Publicity Rules
Brief: Relief Therapeutics Says Partner NRX Pharmaceuticals Submitted Application For Emergency Use Authorization For Aviptadil To FDA
Swiss stocks - Factors to watch on May 25
Brief: Relief's Partner Acer Therapeutics Plans NDA Submission For Acer-001 In Q3 2021
Brief: Relief Gives Update On Drug For Treatment Of Urea Cycle Disorders
Brief: Relief Therapeutics Says APR Applied Pharma Research Starts Clinical Trial With Nasal Spray APR-AOS2020
Brief: Relief Therapeutics Signs Binding Term Sheet With Applied Pharma Research (APR) To Buy All APR's Outstanding Shares
Brief: Relief And Advita Start Phase 2 Trial Of RLF-100 For Prevention Of Acute Respiratory Distress
Swiss pharma firm Relief, U.S. partner fight after hopes dented for COVID-19 drug (updated)
Swiss pharma firm Relief, U.S. partner fight after hopes dented for COVID-19 drug
Brief: Relief Comments On Statements By Neurorx, Inc.
Brief: Relief Therapeutics FY Net Loss Up At CHF 7.8 Million
Swiss stocks - Factors to watch on April 7
Brief: Relief Says Aviptadil Selected For NIH-Sponsored Global Trial
Brief: Relief Therapeutics Aviptadil To Be Included In NIH-Sponsored Clinical Trial In U.S.
Brief: Relief Therapeutics Releases 60-Day Results From Phase 2B/3 Clinical Trial Of Intravenous RLF-100
Acer Therapeutics: Jumps on deal for metabolic disorders treatment
Brief: Relief And Acer Therapeutics Sign License Agreement For Worldwide Development Of ACER-001